AJOVista’s Crinetics Pharmaceuticals CRNX Stock Holding History

AJOVista’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,630	Closed	-$58K	–	162
2023 Q4	$58K	Buy	+1,630	New	+$50K	0.07%	270

Other funds holding CRNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AJOVista's CRNX Position: Q1 2024 in Review

AJOVista sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2024, closing a stake of 1,630 shares — an estimated $58K sold.

AJOVista first reported a position in CRNX in Q4 2023 and held it in 1 quarter. The position peaked at $58K in Q4 2023. 203 funds tracked by Wall St. Rank hold CRNX as of Q1 2024.

AJOVista reported no remaining Crinetics Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
AJOVista sold 1,630 Crinetics Pharmaceuticals shares in Q1 2024, an estimated $58K.
AJOVista first reported a position in Crinetics Pharmaceuticals in Q4 2023 and held it in 1 quarter.
AJOVista's Crinetics Pharmaceuticals position peaked at $58K in Q4 2023.
203 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2024.

Based on AJOVista's 13F filing for Q1 2024, filed 10 May 2024.